Measurement of the Blood Flow of the Liver

Grindlay, John H.; Herrick, J. F.; Mann, Frank C.

doi:10.1152/ajplegacy.1941.132.2.489

Cited by 73 publications

(21 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, it is suggested that normal hepatic blood flow in dogs is subject to wide spontaneous variations. Corrected blood flow measurement is in agreement with hepatic flow studies determined by the thermostromuhr and other methods (7,11,16,17).…”

Section: Discussionsupporting

confidence: 80%

“…(Table V). Grindlay, Herrick, and Mann (17) reported hepatic blood flow in the dog to average 23 ml./Kg./min. without anesthesia and 22.6 ml./Kg./min.…”

Section: Discussionmentioning

confidence: 99%

“…Several studies have indicated an intermittent and irregular rhythmicity of hepatic blood flow which Grindlay, Herrick, and Mann (17) showed may be due to alternate storage and discharge of blood by the liver.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Measurement of Hepatic Blood Flow in the Dog by the Bromsulphalein Method 12

Werner¹,

Horvath²

1952

J. Clin. Invest.

View full text Add to dashboard Cite

Estimation of hepatic blood flow by the bromsulphalein method appears to be based upon meager experimental evidence. Bradley, Ingelfinger, Bradley, and Curry (1) proposed a formula for the estimation of hepatic blood flow in man by measuring the hepatic extraction of bromsulphalein. Myers (2) compared the hepatic blood flow obtained by this method with the hepatic flow determined by urea formation. These An indwelling needle or catheter was also placed in a branch of the femoral artery. All animals were heparinized, 5 mg./Kg. Blood pressures were recorded continuously by Statham strain gauges simultaneously from the femoral artery, right heart, and hepatic vein. A priming dose of bromsulphalein (BSP) was administered to raise the plasma level rapidly and to shorten the time required for equilibration. The priming dose of BSP was followed immediately by infusion of BISP at a constant rate for a period of 80 minutes.In order to maintain a peripheral BSP concentration of less than -mg. per cent or greater than 1 mg.per cent, two rates or two concentrations of BSP infusions were given. The flow was controlled by the use of a Graubard Peterson flowrator. A sample of the infusion fluid was always taken for later analysis. Hepatic venous and peripheral arterial samples were withdrawn simultaneously at 10-minute intervals during the 40 to 80 minutes of each observation.Five ml. of blood were collected in a dry syringe following preliminary flushing of the catheter by withdrawal of several ml. of blood. Ilemolyzed samples were discarded. The hematocrit value was determined by the usual Wintrobe tube technique from samples of blood obtained at the midpoint of measurements of hepatic blood flow. Blood samples were also obtained from the femoral artery and right heart for the estimation of cardiac output by the Fick principle 60 minutes after the infusion had begun. The data on blood pressures and cardiac outputs are being reported in a separate communication. At the end of each period of observation incisions were sutured, 300,000 units of procaine penicillin administered and the dog returned to its cage. No animal was employed either for other observations or repeated hepatic observations until at least two or more weeks had elapsed.BSP was measured calorimetrically in the macro unit of the Evelyn photoelectric colorimeter using filter 580.The calibration curve and the BSP solutions employed in all experiments were prepared from pure BSP powder (Hynson, Westcott, and Dunning).One ml. of plasma was pipetted into an Evelyn colorimeter tube and the volume made up to 10 ml. with isotonic saline. After the initial "blank" reading, 2 drops of concentrated NaOH were added, the mixture well agitated, and a reading taken within one minute of adding the alkali. The BSP concentration was obtained from the galvanometer reading and the calibration curve. All determinations were made in duplicate.433

show abstract

Section: Discussionsupporting

confidence: 80%

“…(Table V). Grindlay, Herrick, and Mann (17) reported hepatic blood flow in the dog to average 23 ml./Kg./min. without anesthesia and 22.6 ml./Kg./min.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Measurement of Hepatic Blood Flow in the Dog by the Bromsulphalein Method 12

Werner¹,

Horvath²

1952

J. Clin. Invest.

View full text Add to dashboard Cite

show abstract

“…Burton-Opitz (1911) and Barcroft & Shore (1912) estimated the mean contribution of this vessel to total hepatic flow to be between 30 and 34 % in the dog and cat. Thermostrohmuhr methods suggested even lower figures; Grindlay et al (1941) claim that the hepatic artery of the dog only carried 14-3 % of total liver blood. The findings of Ginsburg & Grayson (1954) using 'internal calorimetry', suggested that the coeliac axis contributed about 40 % of total hepatic blood.…”

Section: Contribution Of the Hepatic Artery To Liver Blood Flowmentioning

confidence: 96%

The role of the spleen and the hepatic artery in the regulation of liver blood flow

Grayson¹,

Mendel²

1957

The Journal of Physiology

View full text Add to dashboard Cite

“…2.27 MeV, average 0.9 MeV) that have average tissue penetration of 2.5 mm and a maximum penetration of 11mm. Y-90 is produced in nuclear reactors by the neutron bombardment of Yttrium-89 [6]. Later, it is bound to resin or glass microspheres so that is can be used for treatment.…”

Section: Introductionmentioning

confidence: 99%

Yttrium-90 radioembolization for the treatment of unresectable liver cancer: Results of a single center

Özgür¹,

Gündüz²,

Erkılıç³

et al. 2014

Diclemedj

View full text Add to dashboard Cite

ÖZETAmaç: Çalışmamızda kemoterapiden fayda görmeyen, rezeke edilemeyen karaciğer kanserlerinde yttrium-90 (Y-90) resin mikrosfer radyoembolizasyon terapisinin etkinliğinin ortaya konması amaçlanmıştır.Yöntemler: Çalışmaya radyoembolizasyon tedavisi uygulanan, rezeke edilemeyen primer veya gastrointestinal sistemden metastatik 55 hasta dahil edilmiştir. Üç hasta ön değerlendirme anjiografisi sonrasında çalışma dışı bı-rakılmıştır. Kalan 52 hastanın 13'ü (%23.6) hepatosellü-ler karsinoma, 39'u (%76.4) metastatik karaciğer kanseri hastasıdır. Elli iki hasta radyoembolizan tedavi görmüştür. Her hastaya verilen tedavi, Solid Tümörlerde Tedaviye Yanıt Kritirleri'ne (RECIST) göre değerlendirilmiş ve tüm sürvi olasılığı Kaplan-Meier metoduna ile grafik olarak gösterilmiştir.Bulgular: Y-90 tedavisi sonrası 47 hasta takip edilebilmiştir. Hastaların %57'sinde klinik fayda yanıtı alınmış, %43'ünde hastalık progresyon göstermiştir. Hastaların medyan hepatik progresyonsuz survi süresi 3.4 ay (%95 confidence interval (ci): 1.4-5.3), tüm sürvi süresi 11.3 (%95 confidence interval (ci): 8.7-14.03) olarak saptanmıştır.Sonuç: Bu çalışma Y-90 resin mikrosfer radyoembolizan tedavinin rezeke edilemeyen karaciğer kanseri hastalarında etkin olduğunu ortaya koymaktadır.Anahtar kelimeler: Yttrium-90, radyoembolizasyon, anjiografi, karaciğer kanseri ABSTRACT Objective: To determine the effects of yttrium-90 (Y-90) resin microsphere radioembolization therapy on patients with unresectable liver cancer who do not benefit from chemotherapy. Methods:Fifty-five patients underwent radioembolization therapy included in the study whose had unresectable primary or metastatic liver cancer originating from the gastrointestinal tract. Three were excluded from the study after pre-evaluation angiography. Thirteen (23.6%) of the remaining 52 patients had hepatocellular carcinoma and 39 (76.4%) had metastatic liver cancer. Fifty-two patients underwent Y-90 radioembolization treatment. Each patient's response to the administered treatment was evaluated using the Response Evaluation Criteria in Solid Tumors (RECIST) and the overall probability of survival was displayed graphically by the Kaplan-Meier method.Results: After Y-90 therapy, 47 patients were follow-up. While 57% of the patients responded to treatment as clinical benefit, the disease progressed in 43%. The median hepatic progression-free survival time of the patients was 3.4 months (95% confidence interval (ci):1.4-5.3) and the overall survival time was 11.3 months (95%, CI:8.7-14.03). Conclusion:This study emphasizes that Y-90 resin microsphere radioembolization treatment is effective in patients with unresectable liver cancer.

show abstract

Measurement of the Blood Flow of the Liver

Cited by 73 publications

References 0 publications

Measurement of Hepatic Blood Flow in the Dog by the Bromsulphalein Method 12

Measurement of Hepatic Blood Flow in the Dog by the Bromsulphalein Method 12

The role of the spleen and the hepatic artery in the regulation of liver blood flow

Yttrium-90 radioembolization for the treatment of unresectable liver cancer: Results of a single center

Contact Info

Product

Resources

About